Fulcrum Therapeutics, Inc.
NGM: FULCLive Quote
📈 ZcoreAI Score
Our AI model analyzes Fulcrum Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get FULC Z-Score →About Fulcrum Therapeutics, Inc.
Healthcare
Biotechnology
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Fulcrum Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -25.3%, which indicates that capital utilization is currently under pressure.
At a current price of $7.55, FULC currently sits at the 37th percentile of its 52-week range (Range: $2.71 - $15.74).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$502.83M
Trailing P/E
--
Forward P/E
-4.71
Beta (5Y)
3.27
52W High
$15.74
52W Low
$2.71
Avg Volume
1.04M
Day High
Day Low